<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03132714</url>
  </required_header>
  <id_info>
    <org_study_id>rPDT&amp;antibioticsCFA</org_study_id>
    <nct_id>NCT03132714</nct_id>
  </id_info>
  <brief_title>Periodontal Debridement Associated With Systemic Antibiotics and Single/Repeated PDT to Treat Aggressive Periodontitis</brief_title>
  <official_title>Local Effect of Periodontal Debridement Associated With Different Systemic Antibiotic Protocols and Single or Repeated Application of Photodynamic Therapy to Treat Generalized Aggressive Periodontitis: Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Estadual Paulista Júlio de Mesquita Filho</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade Estadual Paulista Júlio de Mesquita Filho</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this project is to compare the efficacy and the local effect of the association of&#xD;
      single or repeated application of photodynamic therapy (PDT) with antibiotic agents using&#xD;
      Amoxicillin + Metronidazole or Clarithromycin in the treatment of patients with Generalized&#xD;
      Aggressive Periodontitis (GAgP).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study methodology is according to CONSORT-STATEMENT 2010 and SPIRIT 2013 for randomized&#xD;
      controlled clinical trials.&#xD;
&#xD;
      Study Design&#xD;
&#xD;
      The study is designed as a prospective, interventional, parallel, blinded, randomized,&#xD;
      controlled clinical trial aimed to compare the efficacy and the local effect of the&#xD;
      association of single or repeated application of photodynamic therapy (PDT) with antibiotic&#xD;
      agents using Amoxicillin + Metronidazole or Clarithromycin in the treatment of patients with&#xD;
      Generalized Aggressive Periodontitis (GAgP).&#xD;
&#xD;
      Source of data&#xD;
&#xD;
      The population of this study will be recruited among patients referred to the Science and&#xD;
      Technology Institute (ICT) - São José dos Campos, College of Dentistry. Each one of 46&#xD;
      patients will have three pockets with probing depth and loss of clinical attachment level ≥5&#xD;
      mm and bleeding on probing not located at furcation sites randomly chosen.&#xD;
&#xD;
      Power calculation&#xD;
&#xD;
      A population of 46 patients (138 periodontal pockets, 3 per patient) that meet the&#xD;
      pre-established criteria will be considered. Considering α = 5% and a β = 5% to detect a&#xD;
      difference of 1 mm between groups in probing depth reduction of pockets ≥5 mm, for a standard&#xD;
      deviation of 0.8 mm, 14 patients will be needed in each group. With a sample of 46 patients&#xD;
      (138 pockets), the study will have a power greater than 95%.&#xD;
&#xD;
      Clinical Parameters&#xD;
&#xD;
      All clinical parameters will be assessed by a single blinded, trained and calibrated examiner&#xD;
      (CFA) before periodontal therapy (baseline) and at 3 and 6 months after using a manual probe.&#xD;
      Measurements will be done at six sites per tooth (mesiobuccal, buccal, disto-buccal,&#xD;
      distolingual, lingual, and mesiolingual) in all teeth, except third molars.&#xD;
&#xD;
      The following clinical parameters will be evaluated: 1) Full-mouth plaque index (FMPI); 2)&#xD;
      Bleeding on probing (BoP); 3) Probing depth (PD): distance from the bottom of sulcus/pocket&#xD;
      to gingival margin; 4) Gingival recession (GM): distance from the free gingival margin to&#xD;
      cement-enamel junction (CEJ); 5) Clinical attachment level (CAL): distance from bottom of&#xD;
      sulcus/pocket to the CEJ. The CEJ will be identified by careful probe on cervical area.&#xD;
&#xD;
      Calibration and Randomization&#xD;
&#xD;
      Initially, a total of ten patients presenting with GAgP will be selected. The designated&#xD;
      examiner (CFA) will measure CAL and PD in all patients twice within 24 hours, with an&#xD;
      interval of ≥ 1 hour between examinations. Then, the measures will be submitted to intraclass&#xD;
      correlation test and the examiner will be judged calibrated if reaches 90% agreement.&#xD;
&#xD;
      Patients will be allocated into two antibiotic groups (that will receive Amoxicillin +&#xD;
      Metronidazole or Clarithromycin) according to a computer-generated list. The allocation will&#xD;
      be implemented by an investigator (NCCS) who was not directly involved in the examination or&#xD;
      treatment procedures. All medication will be prepared and encased in identical opaque coded&#xD;
      bottles by a compounding pharmacy. The same person outside the project will generate a random&#xD;
      sequence regarding the type of PDT application for each patient, for the three previously&#xD;
      selected pockets (single or repeated application of PDT or control), which will be revealed&#xD;
      shortly after the periodontal debridement session.&#xD;
&#xD;
      Treatment Protocols&#xD;
&#xD;
      All patients will be treated with periodontal therapy through of the one-stage, full mouth,&#xD;
      ultrasonic debridement (FMUD). In a single session, patients will receive local anesthesia&#xD;
      and periodontal debridement with ultrasound equipment (Cavitron - Dentsply EUA) and&#xD;
      subgingival tips (UI25KSF10S, Hu-Friedy). All diseased sites will be instrumented in this one&#xD;
      session. The debridement session will be performed by a single experienced and trained&#xD;
      periodontist (NA), different from the examiner (ca). Immediately before the mechanical&#xD;
      therapy, patients will be allocated in one of the two treatment protocols: Clarithromycin&#xD;
      (CLM) group (n = 22): FMUD + CLM 500 mg bid, for 7 days or Amoxicillin (AMX) + metronidazole&#xD;
      (MET) group (n = 22): FMUD + (AMX 500 mg tid + MET 400 mg tid, both for 7 days. All patients&#xD;
      will start taking the pills immediately before the FMUD session.&#xD;
&#xD;
      After periodontal debridement (PD), two periodontal pockets from each patient will receive&#xD;
      the proposed PDT protocols to assist the decontamination of diseased sites. One pocket will&#xD;
      receive a single application of PDT (sPDT) (baseline only) and the other will receive&#xD;
      repeated application of PDT (rPDT). After subgingival irrigation with saline solution to wash&#xD;
      the pocket, the photosensitizer (methylene blue 10 mg / mL) will be applied to the bottom of&#xD;
      the pocket by buccal side until it is completely filled. After one minute, the pocket will be&#xD;
      washed with water and exposed to low-level laser (TheraLase - Brazil), with a corresponding&#xD;
      optical fiber of 600 um diameter, which will be inserted into the pocket. A 660 nm wavelength&#xD;
      with a power of 60 milliwatts and a dose of 129 J / cm2 will be used for one minute. The same&#xD;
      procedure will be repeated by lingual site, totaling two minutes of application per pocket.&#xD;
      The repeated application protocol will consist of 5 applications on different days, performed&#xD;
      on the day of periodontal treatment (baseline - 0), 1, 2, 7 and 14 days after. Thus, the&#xD;
      following comparative groups will be formed, totaling 138 pockets:&#xD;
&#xD;
      PD + (AMX + MET) (n = 23): periodontal pockets that will receive periodontal debridement&#xD;
      associated with Amoxicillin + Metronidazole;&#xD;
&#xD;
      PD + CLM (n = 23): periodontal pockets that will receive periodontal debridement associated&#xD;
      with the use of Clarithromycin;&#xD;
&#xD;
      PD + (AMX + MET) + sPDT (n = 23): periodontal pockets that will receive periodontal&#xD;
      debridement associated with Amoxicillin + Metronidazole and single application of PDT; PD +&#xD;
      CLM + sPDT (n = 23): periodontal pockets that will receive periodontal debridement associated&#xD;
      with the use of Clarithromycin and single application of PDT;&#xD;
&#xD;
      PD + (AMX + MET) + rPDT (n = 23) : periodontal pockets that will receive periodontal&#xD;
      debridement associated with Amoxicillin + Metronidazole and repeated application of PDT;&#xD;
&#xD;
      PD + CLM + rPDT (n = 23): periodontal pockets that will receive periodontal debridement&#xD;
      associated with Clarithromycin and repeated application of PDT&#xD;
&#xD;
      Statistical analysis&#xD;
&#xD;
      Mean and standard deviation will be calculated for each parameter. The normal distribution of&#xD;
      the data will be analyzed by Shapiro-Wilk test. Data from clinical measurements will be&#xD;
      subjected to analysis of variance (repeated measures) for inter and intra-group comparison.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Probing Depth (PD)</measure>
    <time_frame>0, 3 and 6 post-operatively</time_frame>
    <description>Evaluate the difference between baseline and 6 months PD measures.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Aggressive Periodontitis, Generalized</condition>
  <arm_group>
    <arm_group_label>PD + (AMX + MET)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Amoxicillin 500 mg + Metronidazole 400 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PD + CLM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic clarithromycin 500 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PD + (AMX + MET) + sPDT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Amoxicillin 500 mg + Metronidazole 400 mg and single application of PDT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PD + CLM + sPDT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Clarithromycin 500 mg and single application of PDT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PD + (AMX + MET) + rPDT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Amoxicillin 500 mg + Metronidazole 400 mg and repeated application of PDT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PD + CLM + rPDT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Clarithromycin 500 mg and repeated application of PDT</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Full-mouth ultrasonic debridement</intervention_name>
    <description>Full-mouth ultrasonic debridement will be performed in order to treat diseased sites</description>
    <arm_group_label>PD + (AMX + MET)</arm_group_label>
    <arm_group_label>PD + (AMX + MET) + rPDT</arm_group_label>
    <arm_group_label>PD + (AMX + MET) + sPDT</arm_group_label>
    <arm_group_label>PD + CLM</arm_group_label>
    <arm_group_label>PD + CLM + rPDT</arm_group_label>
    <arm_group_label>PD + CLM + sPDT</arm_group_label>
    <other_name>Periodontal debridement</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin 500mg</intervention_name>
    <description>Administration of Amoxicillin 500mg tid for 7 days</description>
    <arm_group_label>PD + (AMX + MET)</arm_group_label>
    <arm_group_label>PD + (AMX + MET) + rPDT</arm_group_label>
    <arm_group_label>PD + (AMX + MET) + sPDT</arm_group_label>
    <other_name>Amoxil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole 400mg</intervention_name>
    <description>Administration of Metronidazole 400mg tid for 7 days.</description>
    <arm_group_label>PD + (AMX + MET)</arm_group_label>
    <arm_group_label>PD + (AMX + MET) + rPDT</arm_group_label>
    <arm_group_label>PD + (AMX + MET) + sPDT</arm_group_label>
    <other_name>Flagyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin 500mg</intervention_name>
    <description>Administration of Clarithromycin 500mg bid for 7 days</description>
    <arm_group_label>PD + CLM</arm_group_label>
    <arm_group_label>PD + CLM + rPDT</arm_group_label>
    <arm_group_label>PD + CLM + sPDT</arm_group_label>
    <other_name>Biaxin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Single application of PDT</intervention_name>
    <description>Single application of photodynamic therapy (PDT) at day 0.</description>
    <arm_group_label>PD + (AMX + MET) + sPDT</arm_group_label>
    <arm_group_label>PD + CLM + sPDT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Repeated application of PDT</intervention_name>
    <description>Repeated application of photodynamic therapy (PDT) at 0, 1, 2, 7 and 14 days post-operatively.</description>
    <arm_group_label>PD + (AMX + MET) + rPDT</arm_group_label>
    <arm_group_label>PD + CLM + rPDT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosis of GAgP (Armitage, 1999; American Academy of Periodontology, 2015);&#xD;
&#xD;
          -  presence of ≥20 teeth, excluding third molars and teeth indicated for extraction;&#xD;
&#xD;
          -  presence of ≥6 sites presenting PD ≥5 mm with bleeding on probing and ≥2 sites with PD&#xD;
             ≥7 mm (including incisors and first molars, in addition to two other non-contiguous&#xD;
             teeth between them);&#xD;
&#xD;
          -  presence of three non-adjacent periodontal pockets with probing depth ≥5 mm and&#xD;
             bleeding on probing not located in furcation area;&#xD;
&#xD;
          -  good general health (ASA I/II);&#xD;
&#xD;
          -  18-35 years old;&#xD;
&#xD;
          -  agree to participate in the study and sign a written consent (Resolution # 196 of&#xD;
             October 1996 and the Brazilian Professional Code of Dental Ethics - 179/93).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnant or nursing;&#xD;
&#xD;
          -  suffer from any systemic disease (e.g. cardiovascular, diabetes, blood dyscrasias,&#xD;
             immunodeficiency, etc - ASA III/IV/V);&#xD;
&#xD;
          -  antimicrobials or anti-inflammatory drugs in the previous 6 months;&#xD;
&#xD;
          -  periodontal treatment within the last 12 months;&#xD;
&#xD;
          -  smoke ≥10 cigarettes/day;&#xD;
&#xD;
          -  reported allergy to amoxicillin, metronidazole or clarithromycin;&#xD;
&#xD;
          -  required antibiotic prophylaxis;&#xD;
&#xD;
          -  current use of any medication that could interfere with periodontal response were&#xD;
             excluded from the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mauro P Santamaria, DDS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidade Estadual Paulista Júlio de Mesquita Filho</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>College of Dentistry - São José dos Campos, São Paulo State University</name>
      <address>
        <city>Sao Jose dos Campos</city>
        <state>SP</state>
        <zip>12245-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Lulic M, Leiggener Görög I, Salvi GE, Ramseier CA, Mattheos N, Lang NP. One-year outcomes of repeated adjunctive photodynamic therapy during periodontal maintenance: a proof-of-principle randomized-controlled clinical trial. J Clin Periodontol. 2009 Aug;36(8):661-6. doi: 10.1111/j.1600-051X.2009.01432.x. Epub 2009 Jun 25.</citation>
    <PMID>19563331</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>April 23, 2017</study_first_submitted>
  <study_first_submitted_qc>April 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2017</study_first_posted>
  <last_update_submitted>April 26, 2017</last_update_submitted>
  <last_update_submitted_qc>April 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Estadual Paulista Júlio de Mesquita Filho</investigator_affiliation>
    <investigator_full_name>Mauro Pedrine Santamaria</investigator_full_name>
    <investigator_title>PhD Adjunct professor</investigator_title>
  </responsible_party>
  <keyword>Full-mouth ultrasonic debridement</keyword>
  <keyword>Clarithromycin</keyword>
  <keyword>Amoxicillin</keyword>
  <keyword>Metronidazole</keyword>
  <keyword>Antimicrobial therapy</keyword>
  <keyword>Photodynamic therapy</keyword>
  <keyword>Low-level laser therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontitis</mesh_term>
    <mesh_term>Aggressive Periodontitis</mesh_term>
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

